Outcome of antiviral therapy in Egyptian Hepatitis C Virus (HCV) genotype 4 patients with advanced liver fibrosis

European Journal of Internal Medicine

Volumn 23, Issue 1, 2012, Pages

  El Khattib, Ahmed A ^a   Abdelhakam, Sara M ^a   Ghoraba, Dalia M ^a   Ibrahim, Wesam A ^a   Sayed, Moataz M ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Advanced fibrosis; Genotype 4; Hepatitis C virus; Pegylated interferon; Ribavirin; Treatment outcomes

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; CHRONIC DISEASE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIVER FIBROSIS; RELAPSE; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS;

EID: 83555176109     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.10.003     Document Type: Letter

References (8)

1. N. Abd El Ghaffar, W. Rasheed, M. Harvi, and H. Assal New markers for evaluation of the efficacy of interferon-alfa therapy in HCV patients Res J Med Med Sci 4 2009 196 201
2. G.T. Everson, J. Trotter, L. Forman, M. Kugelmas, A. Halprin, and B. Fey Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy Hepatology 42 2005 255 262 (Pubitemid 41061075)
3. T. Poynard, J. McHutchison, M. Manns, C. Trepo, K. Lindsay, and Z. Goodman PEG-Fibrosis Project Group. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313 (Pubitemid 34465173)
4. M. Derbala, A. Amer, A. Bener, A.C. Lopez, M. Omar, and M. El Ghannam Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis J Viral Hepat 12 2005 380 385 (Pubitemid 40961477)
5. T. Poynard, J. McHutchison, Z. Goodman, M.H. Ling, and J. Albrecht Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group Hepatology 31 2000 211 218 (Pubitemid 30033709)
6. R. Grieve, J. Roberts, M. Wright, M. Sweeting, D. DeAngelis, and W. Rosenberg Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C Gut 55 2006 1332 1338 (Pubitemid 44277366)
7. L. Gheorghe, S. Iacob, M. Grigorescu, I. Sporea, R. Sirli, and D. Damian High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C J Gastrointestin Liver Dis 18 2009 51 56
8. S. Bruno, M.L. Shiffman, S.K. Roberts, E.J. Gane, D. Messinger, and S.J. Hadziyannis Efficacy and safety of peg interferon Alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis Hepatology 51 2010 388 397